| abstract |
The present invention provides a pharmaceutical composition comprising a JAK kinase inhibitor of Formula Ia, an enantiomer, diastereomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a compound of Formula Ia, A pharmaceutical composition comprising an acceptable carrier, adjuvant or vehicle, and a method of treating or reducing the severity of a disease or condition responsive to inhibition of JAK kinase activity in a patient. <Formula Ia> |